Zusammenfassung
Stammzelltherapie zur Behandlung von Knorpelschäden und Arthrose ist in aller Munde und stellt für den Arzt, aber auch für viele Patienten einen höchst attraktiv anmutenden Therapieansatz mit hohem Innovationsgrad dar. Dennoch erscheint der Bereich der Zelltherapie nicht unproblematisch. So sind Zell- und Gewebstherapeutika in Deutschland durch die Verordnung von Arzneimitteln für neuartige Therapieansätze (ATMP) im Sinne des Arzneimittelgesetzes reguliert, und es besteht eine große Heterogenität bei den Anwendungsmöglichkeiten. Zudem lässt sich die aktuell verfügbare geringe wissenschaftliche Evidenz nur schwer einordnen. Nicht nur vor diesem Hintergrund sind aus Sicht der Autoren hier kontrollierte Studien mit spezifischen Fragestellungen zu fordern, bevor diese Therapieansätze den Patienten in der Breite angeboten werden. Der vorliegende Artikel umfasst die unterschiedlichen Aspekte der aktuellen Problematik in Bezug auf die Anwendung von Zell- und Gewebetherapien in Deutschland.
Abstract
Stem cell therapy for the treatment of cartilage damage and osteoarthritis is a widely discussed topic of increasing interest. For both clinicians and patients it is considered a highly attractive therapeutic approach associated with a high degree of innovation. Nevertheless, the field of cell therapy does not seem to be unproblematic. Thus, cell and tissue therapeutic agents are controlled in Germany by the regulation for drugs for advanced therapy medicinal products (ATMP) and there is a wide heterogeneity in the possibilities of application. In addition, the currently available limited scientific evidence is difficult to classify. It is not only against this background that, from the authors’ point of view, controlled studies with specific questions need to be performed before these therapeutic approaches are offered to patients in the daily routine. This article covers the different aspects of the current problem in relation to the application of cell and tissue therapies in Germany.
This is a preview of subscription content, access via your institution.
Literatur
Akgun I, Unlu MC, Erdal O et al (2014) Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-014-2136-z
Albrecht D, Niemeyer P, Ju MJF (2016) Cartilage repair surgery for full-thickness defects of the knee in Germany : indications and epidemiological data from the German Cartilage Registry (KnorpelRegister DGOU) https://doi.org/10.1007/s00402-016-2453-5
Davies BM, Snelling SJ, Quek L et al (2016) Identifying the optimum source of mesenchymal stem cells for use in knee surgery. J Orthop Res 35(9):1–27. https://doi.org/10.1002/jor.23501
de Girolamo L, Bertolini G, Cervellin M et al (2010) Treatment of chondral defects of the knee with one step matrix-assisted technique enhanced by autologous concentrated bone marrow: in vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. Injury 41:1172–1177. https://doi.org/10.1016/j.injury.2010.09.027
Gobbi A, Karnatzikos G, Sankineani SR (2014) One-step surgery with multipotent stem cells for the treatment of large full-thickness chondral defects of the knee. Am J Sports Med 42:648–657. https://doi.org/10.1177/0363546513518007
Heir S, Nerhus TK, Røtterud JH et al (2010) Focal cartilage defects in the knee impair quality of life as much as severe osteoarthritis: a comparison of knee injury and osteoarthritis outcome score in 4 patient categories scheduled for knee surgery. Am J Sports Med 38:231–237. https://doi.org/10.1177/0363546509352157
Im G‑I, Shin Y‑W, Lee K‑B (2005) Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthr Cartil 13:845–853. https://doi.org/10.1016/j.joca .2005.05.005
Kim YS, Kwon OR, Choi YJ (2015) Comparative matched-pair analysis of the injection versus implantation of mesenchymal stem cells for knee osteoarthritis, S 1–9 https://doi.org/10.1177/0363546515599632
Koh Y‑G, Kwon O‑R, Kim Y‑S et al (2016) Adipose-derived Mesenchymal stem cells with Microfracture versus microfracture alone: 2‑year follow-up of a prospective randomized trial. Arthrosc J Arthrosc Relat Surg 32:97–109. https://doi.org/10.1016/j.arthro.2015.09.010
Kubosch EJ, Heidt E, Niemeyer P et al (2017) In-vitro chondrogenic potential of synovial stem cells and chondrocytes allocated for autologous chondrocyte implantation—a comparison: Synovial stem cells as an alternative cell source for autologous chondrocyte implantation. Int Orthop. https://doi.org/10.1007/s00264-017-3400-y
Nejadnik H, Hui JH, Feng Choong EP et al (2010) Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med 38:1110–1116. https://doi.org/10.1177/0363546509359067
Niemeyer P, Feucht MJ, Fritz J et al (2016) Cartilage repair surgery for full-thickness defects of the knee in Germany: indications and epidemiological data from the German Cartilage Registry (KnorpelRegister DGOU). Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-016-2453-5
Park Y‑B, Ha C‑W, Rhim JH, Lee H‑J (2018) Stem cell therapy for articular cartilage repair: review of the entity of cell populations used and the result of the clinical application of each entity. Am J Sports Med 46:2540–2552. https://doi.org/10.1177/0363546517729152
Pers Y‑M, Rackwitz L, Ferreira R et al (2016) Adipose Mesenchymal Stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cells Transl Med 5:847–856. https://doi.org/10.5966/sctm.2015-0245
Sanzenbacher R, Frech M (2019) Streitpunkt Eigenfettbehandlung: Wenn Gewebe zur Arznei wird. Dtsch Ärtzeblatt 116:28–30
Schmal H, Kowal JM, Kassem M et al (2018) Comparison of regenerative tissue quality following matrix-associated cell implantation using amplified Chondrocytes compared to Synovium-derived stem cells in a rabbit model for cartilage lesions. Stem Cells Int 2018:4142031. https://doi.org/10.1155/2018/4142031
Seil R, Ayeni OR, Hirschmann MT (2018) Technological innovation in orthopaedic surgery: balancing innovation and science with clinical and industry interests. Knee Surg Sports Traumatol Arthrosc 26:2223–2226. https://doi.org/10.1007/s00167-018-4990-7
Skowroński J, Skowroński R, Rutka M (2013) Large cartilage lesions of the knee treated with bone marrow concentrate and collagen membrane—results. Ortop Traumatol Rehabil 15:69–76. https://doi.org/10.5604/15093492.1012405
Strioga M, Viswanathan S, Darinskas A et al (2012) Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 21:2724–2752. https://doi.org/10.1089/scd.2011.0722
Zorzi C, Piovan G, Bonetti S et al (2018) Autologous micro-fragmented adipose tissue for the treatment of diffuse degenerative knee osteoarthritis: an update at 3 year follow-up. J Exp Orthop. https://doi.org/10.1186/s40634-018-0169-x
https://www.pei.de/SharedDocs/Downloads/pu/innovationsbuero/entscheidungsbaum-atmp.pdf?__blob=publicationFile&v=3. Zugegriffen: 9. März 2019
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P. Niemeyer und M.T. Hirschmann geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Niemeyer, P., Hirschmann, M.T. Zukunftsperspektive „Stammzelltherapie“ in Deutschland. Arthroskopie 32, 205–211 (2019). https://doi.org/10.1007/s00142-019-0279-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00142-019-0279-1